https://m2.mtmt.hu/ hun 2026-09-22 15:46 JournalArticle 34573098 VALIDATED true 0 false 2026-09-15T11:45:24.747+0000 2026-09-15T11:44:15.227+0000 2024-02-12T10:16:26.651+0000 true 10045296 Cseh Éva /api/admin/10045296 Admin Cseh Éva (SE_AOK_Adm5_1GyermekgyCsehÉva, admin) true 10045296 2026-09-15T11:44:15.650+0000 2026-09-15T11:44:15.650+0000 2024-04-21T16:16:28.541+0000 true 10082843 Berhidi Anna /api/admin/10082843 Admin Berhidi Anna (SE_ÁOK_Sebészet_Admin5_BA, admin) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Moldvai, Dorottya true true /api/journal/809 REVIEWED BRITISH JOURNAL OF CANCER 0007-0920 1532-1827 true false 809 false 809 true 0007-0920 1532-1827 Journal FOREIGN 130 7 1119 1130 1119 12 2024 Funding 2037397 /api/funding/2037397 (National Bionics Programme ED_17-1-2017-0009) Támogató: NKFIH false true Funding 2037398 /api/funding/2037398 (TKP2021-EGA-24) false true Funding 2037399 /api/funding/2037399 (FK-128404) Támogató: NKFIH false true Funding 2037400 /api/funding/2037400 (K-142799) Támogató: NKFI false true Funding 2037401 /api/funding/2037401 (PD-131637) false true Funding 2037402 /api/funding/2037402 Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009) Támogató: EFOP-VEKOP false true Funding 2037403 /api/funding/2037403 (ÚNKP-22-4-I-SE-12) false true Funding 2037404 /api/funding/2037404 (LP2021-3/2021) false true Funding 2037405 /api/funding/2037405 (Open access funding provided by Semmelweis University) false true true 2024 true true true false true false GOLD 2026-09-15 true https://doi.org/10.1038/s41416-024-02597-8 4 0 4 3 1 4 4 4 4 4 4 3 3 3 1 0 4 3 4 3 0 8 8 Folyóiratcikk Journal Article 24 4 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2024 0 1 1 1 1 2025 0 3 2 3 2 D1 false 10051986,10000745 false false false 2024-04-20T16:16:21.992+0000 Gyermekgyógyászati Klinika (SE / AOK / K); MTA-SE Lendület Diabétesz Kutatócsoport (SE / AOK / K / GYGYK); Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I); Sebészeti, Transzplantációs és Gasztroenterológ... (SE / AOK / K) 13 36 4 13 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 114364531 /api/authorship/114364531 Moldvai, Dorottya [Moldvai, Dorottya (Tumorbiológia), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 1 0.077 true false false Author 10078438 /api/author/10078438 Moldvai Dorottya (Tumorbiológia) Moldvai Dorottya true true Moldvai Dorottya true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364532 /api/authorship/114364532 Sztankovics, Dániel [Sztankovics, Dániel (Onkológia), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 2 0.077 false false false Author 10074525 /api/author/10074525 Sztankovics Dániel (Onkológia) Sztankovics Dániel true true Sztankovics Dániel true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364533 /api/authorship/114364533 Dankó, Titanilla [Dankó, Titanilla (Tumorbiológia), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 3 0.077 false false false Author 10065723 /api/author/10065723 Dankó Titanilla (Tumorbiológia) Dankó Titanilla true true Dankó Titanilla true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364534 /api/authorship/114364534 Vetlényi, Enikő [Vetlényi, Enikő Judit (Onkológia), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 4 0.077 false false false Author 10059474 /api/author/10059474 Vetlényi Enikő Judit (Onkológia) Vetlényi Enikő Judit true 10059474 true Vetlényi Enikő true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364535 /api/authorship/114364535 Petővári, Gábor [Petővári, Gábor (Tumorbiológia), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 5 0.077 false false false Author 10051987 /api/author/10051987 Petővári Gábor (Tumorbiológia) Petővári Gábor true 10051987 true Petővári Gábor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364536 /api/authorship/114364536 Márk, Ágnes [Márk, Ágnes (Hematopatológia), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 6 0.077 false false false Author 10035394 /api/author/10035394 Márk Ágnes (Hematopatológia) Márk Ágnes true 10035394 true Márk Ágnes true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364537 /api/authorship/114364537 Patonai, Attila [Patonai, Attila (belgyógyászat, pa...), szerző] Sebészeti, Transzplantációs és Gasztroenterológ... (SE / AOK / K) 7 0.077 false false false Author 10024162 /api/author/10024162 Patonai Attila (belgyógyászat, patológia) Patonai Attila true 10024162 true Patonai Attila true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364538 /api/authorship/114364538 Végső, Gyula [Végső, Gyula (sebészet), szerző] Sebészeti, Transzplantációs és Gasztroenterológ... (SE / AOK / K) 8 0.077 false false false Author 10024127 /api/author/10024127 Végső Gyula (sebészet) Végső Gyula true 10024127 true Végső Gyula true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364539 /api/authorship/114364539 Piros, László [Piros, László (sebészet), szerző] Sebészeti, Transzplantációs és Gasztroenterológ... (SE / AOK / K) 9 0.077 false false false Author 10024125 /api/author/10024125 Piros László (sebészet) Piros László true 10024125 true Piros László true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364540 /api/authorship/114364540 Hosszú, Ádám [Hosszú, Ádám (nephrológia), szerző] MTA-SE Lendület Diabétesz Kutatócsoport (SE / AOK / K / GYGYK); Gyermekgyógyászati Klinika (SE / AOK / K) 10 0.077 false false false Author 10032730 /api/author/10032730 Hosszú Ádám (nephrológia) Hosszú Ádám true 10032730 true Hosszú Ádám true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364541 /api/authorship/114364541 Pápay, Judit [Pápay, Judit (Patológia), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 11 0.077 false false false Author 10023572 /api/author/10023572 Pápay Judit (Patológia) Pápay Judit true 10023572 true Pápay Judit true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364542 /api/authorship/114364542 Krencz, Ildikó** [Krencz, Ildikó (Tüdődaganatok), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 12 0.077 false true false Author 10051986 /api/author/10051986 Krencz Ildikó (Tüdődaganatok) Krencz Ildikó true 10051986 true Krencz Ildikó true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 114364543 /api/authorship/114364543 Sebestyén, Anna ✉ [Sebestyén, Anna (Tumorbiológia), szerző] Patológiai és Kísérleti Rákkutató Intézet (SE / AOK / I) 13 0.077 false true true Author 10000745 /api/author/10000745 Sebestyén Anna (Tumorbiológia) Sebestyén Anna true 10000745 true Sebestyén Anna true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 25461427 /api/publicationidentifier/25461427 DOI: 10.1038/s41416-024-02597-8 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1038/s41416-024-02597-8 https://doi.org/10.1038/s41416-024-02597-8 false true PublicationIdentifier 25715705 /api/publicationidentifier/25715705 WoS: 001161221700001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001161221700001 https://www.webofscience.com/wos/woscc/full-record/001161221700001 false true PublicationIdentifier 25630980 /api/publicationidentifier/25630980 Scopus: 85184499042 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85184499042 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85184499042 true true PublicationIdentifier 25630995 /api/publicationidentifier/25630995 PubMed: 38341510 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 38341510 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38341510&dopt=Abstract true true Classification 12215 /api/classification/12215 Klinikai orvostan true true Classification 12306 /api/classification/12306 Onkológia true true Classification 12124 /api/classification/12124 Orvos- és egészségtudomány true true SjrRating 11488718 /api/sjrrating/11488718 sjr:D1 (2024) Scopus - Oncology BRITISH JOURNAL OF CANCER 0007-0920 1532-1827 34 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2730 /api/classificationexternal/2730 Scopus - Oncology true 2730 true D1 DIRECT true true Reference 50002314 /api/reference/50002314 1. Karami S, Yanik EL, Moore LE, Pfeiffer RM, Copeland G, Gonsalves L, et al. Risk of Renal Cell Carcinoma Among Kidney Transplant Recipients in the United States. Am J Transpl. 2016;16:3479–89., DOI: 10.1111/ajt.13862 1 10.1111/ajt.13862 false true Reference 50002315 /api/reference/50002315 2. Friman TK, Jäämaa-Holmberg S, Åberg F, Helanterä I, Halme M, Pentikäinen MO, et al. Cancer risk and mortality after solid organ transplantation: A population-based 30-year cohort study in Finland. Int J Cancer. 2022;150:1779–91., DOI: 10.1002/ijc.33934 2 10.1002/ijc.33934 false true Reference 50002316 /api/reference/50002316 3. Végső G, Tóth A, Toronyi É, Perner F, Máthé Z. Changes in Tumor Characteristics in Kidney Transplanted Patients Over the Last 40 Years. Transpl Proc. 2015;47:2198–200., DOI: 10.1016/j.transproceed.2015.07.021 3 10.1016/j.transproceed.2015.07.021 false true Reference 50002317 /api/reference/50002317 4. Blosser CD, Haber G, Engels EA. Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period. Kidney Int. 2021;99:1430–8., DOI: 10.1016/j.kint.2020.10.018 4 10.1016/j.kint.2020.10.018 false true Reference 50002318 /api/reference/50002318 5. Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun. 1989;2:723–31., DOI: 10.1016/S0896-8411(89)80010-1 5 10.1016/S0896-8411(89)80010-1 false true Reference 50002319 /api/reference/50002319 6. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351:623–8., DOI: 10.1016/S0140-6736(97)08496-1 6 10.1016/S0140-6736(97)08496-1 false true Reference 50002320 /api/reference/50002320 7. Langeland T, Engh V. Topical use of tacrolimus and squamous cell carcinoma on the penis. Br J Dermatol. 2005;152:183–5., DOI: 10.1111/j.1365-2133.2004.06315.x 7 10.1111/j.1365-2133.2004.06315.x false true Reference 50002321 /api/reference/50002321 8. Castellsague J, Kuiper JG, Pottegård A, Anveden Berglind I, Dedman D, Gutierrez L, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). Clin Epidemiol. 2018;10:299–310., DOI: 10.2147/CLEP.S146442 8 10.2147/CLEP.S146442 false true Reference 50002322 /api/reference/50002322 9. Asgari MM, Tsai AL, Avalos L, Sokil M, Quesenberry CP Jr. Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis. JAMA Dermatol. 2020;156:1066–73., DOI: 10.1001/jamadermatol.2020.2240 9 10.1001/jamadermatol.2020.2240 false true Reference 50002323 /api/reference/50002323 10. Arana A, Pottegård A, Kuiper JG, Booth H, Reutfors J, Calingaert B, et al. Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clin Epidemiol. 2021;13:1141–53., DOI: 10.2147/CLEP.S331287 10 10.2147/CLEP.S331287 false true Reference 50002324 /api/reference/50002324 11. Devasenapathy N, Chu A, Wong M, Srivastava A, Ceccacci R, Lin C, et al. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2023;7:13–25., DOI: 10.1016/S2352-4642(22)00283-8 11 10.1016/S2352-4642(22)00283-8 false true Reference 50002325 /api/reference/50002325 12. Undre NA, Moloney FJ, Ahmadi S, Stevenson P, Murphy GM. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2009;160:665–9., DOI: 10.1111/j.1365-2133.2008.08974.x 12 10.1111/j.1365-2133.2008.08974.x false true Reference 50002326 /api/reference/50002326 13. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharm. 1977;55:48–51., DOI: 10.1139/y77-007 13 10.1139/y77-007 false true Reference 50002327 /api/reference/50002327 14. Eng CP, Sehgal SN, Vézina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot. 1984;37:1231–7., DOI: 10.7164/antibiotics.37.1231 14 10.7164/antibiotics.37.1231 false true Reference 50002328 /api/reference/50002328 15. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:706–20., DOI: 10.1093/annonc/mdz056 15 10.1093/annonc/mdz056 false true Reference 50002329 /api/reference/50002329 16. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335–40., DOI: 10.1016/S0009-9120(98)00045-9 16 10.1016/S0009-9120(98)00045-9 false true Reference 50002330 /api/reference/50002330 17. Yanik EL, Gustafson SK, Kasiske BL, Israni AK, Snyder JJ, Hess GP, et al. Sirolimus use and cancer incidence among US kidney transplant recipients. Am J Transpl. 2015;15:129–36., DOI: 10.1111/ajt.12969 17 10.1111/ajt.12969 false true Reference 50002331 /api/reference/50002331 18. Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;349:g6679., DOI: 10.1136/bmj.g6679 18 10.1136/bmj.g6679 false true Reference 50002332 /api/reference/50002332 19. Schmucki K, Hofmann P, Fehr T, Inci I, Kohler M, Schuurmans MM. Mammalian Target of Rapamycin Inhibitors and Kidney Function After Thoracic Transplantation: A Systematic Review and Recommendations for Management of Lung Transplant Recipients. Transplantation. 2023;107:53–73., DOI: 10.1097/TP.0000000000004336 19 10.1097/TP.0000000000004336 false true Reference 50002333 /api/reference/50002333 20. Naik MG, Arns W, Budde K, Diekmann F, Eitner F, Gwinner W, et al. Sirolimus in renal transplant recipients with malignancies in Germany. Clin Kidney J. 2021;14:2047–58., DOI: 10.1093/ckj/sfaa262 20 10.1093/ckj/sfaa262 false true Reference 50002334 /api/reference/50002334 21. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233–42., DOI: 10.1097/TP.0b013e3181927a41 21 10.1097/TP.0b013e3181927a41 false true Reference 50002335 /api/reference/50002335 22. Trattner A, Hodak E, David M, Sandbank M. The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer. 1993;72:1779–83., DOI: 10.1002/1097-0142(19930901)72:5&lt;1779::AID-CNCR2820720543&gt;3.0.CO;2-M 22 10.1002/1097-0142(19930901)72:5&lt;1779::AID-CNCR2820720543&gt;3.0.CO;2-M false true Reference 50002336 /api/reference/50002336 23. Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC. Azathioprine and Risk of Skin Cancer in Organ Transplant Recipients: Systematic Review and Meta-Analysis. Am J Transplant. 2016;16:3490–503., DOI: 10.1111/ajt.13863 23 10.1111/ajt.13863 false true Reference 50002337 /api/reference/50002337 24. Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. Jama. 2006;296:2823–31., DOI: 10.1001/jama.296.23.2823 24 10.1001/jama.296.23.2823 false true Reference 50002338 /api/reference/50002338 25. Huynh TP, Barwe SP, Lee SJ, McSpadden R, Franco OE, Hayward SW, et al. Glucocorticoids suppress renal cell carcinoma progression by enhancing Na,K-ATPase beta-1 subunit expression. PLoS One. 2015;10:e0122442., DOI: 10.1371/journal.pone.0122442 25 10.1371/journal.pone.0122442 false true Reference 50002339 /api/reference/50002339 26. Engberg H, Wehberg S, Bistrup C, Heaf J, Sørensen SS, Thiesson HC, et al. Cancer risk and mortality after kidney transplantation: a population-based study on differences between Danish centres using standard immunosuppression with and without glucocorticoids. Nephrol Dial Transpl. 2016;31:2149–56., DOI: 10.1093/ndt/gfw304 26 10.1093/ndt/gfw304 false true Reference 50002340 /api/reference/50002340 27. Hirunsatitpron P, Hanprasertpong N, Noppakun K, Pruksakorn D, Teekachunhatean S, Koonrungsesomboon N. Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta-analysis. Br J Clin Pharm. 2022;88:476–89., DOI: 10.1111/bcp.14979 27 10.1111/bcp.14979 false true Reference 50002341 /api/reference/50002341 28. Eberhard OK, Kliem V, Brunkhorst R. Five cases of Kaposi’s sarcoma in kidney graft recipients: possible influence of the immunosuppressive therapy. Transplantation. 1999;67:180–4., DOI: 10.1097/00007890-199901150-00030 28 10.1097/00007890-199901150-00030 false true Reference 50002342 /api/reference/50002342 29. Penn I. Primary kidney tumors before and after renal transplantation. Transplantation. 1995;59:480–5., DOI: 10.1097/00007890-199559040-00006 29 10.1097/00007890-199559040-00006 false true Reference 50002343 /api/reference/50002343 30. Leveridge M, Musquera M, Evans A, Cardella C, Pei Y, Jewett M, et al. Renal cell carcinoma in the native and allograft kidneys of renal transplant recipients. J Urol. 2011;186:219–23., DOI: 10.1016/j.juro.2011.03.032 30 10.1016/j.juro.2011.03.032 false true Reference 50002344 /api/reference/50002344 31. Tillou X, Guleryuz K, Collon S, Doerfler A. Renal cell carcinoma in functional renal graft: Toward ablative treatments. Transpl Rev. 2016;30:20–6., DOI: 10.1016/j.trre.2015.07.001 31 10.1016/j.trre.2015.07.001 false true Reference 50002345 /api/reference/50002345 32. Krencz I, Sebestyén A, Fábián K, Márk Á, Moldvay J, Khoor A, et al. Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma. Hum Pathol. 2017;62:66–73., DOI: 10.1016/j.humpath.2016.12.012 32 10.1016/j.humpath.2016.12.012 false true Reference 50002346 /api/reference/50002346 33. Cairns P. Renal cell carcinoma. Cancer Biomark. 2010;9:461–73., DOI: 10.3233/CBM-2011-0176 33 10.3233/CBM-2011-0176 false true Reference 50002347 /api/reference/50002347 34. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001;59:3–16., DOI: 10.1046/j.1523-1755.2001.00460.x 34 10.1046/j.1523-1755.2001.00460.x false true Reference 50002348 /api/reference/50002348 35. Han SS, Kim DH, Lee SM, Han NY, Oh JM, Ha J, et al. Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants. Kidney Res Clin Pr. 2012;31:157–62., DOI: 10.1016/j.krcp.2012.06.007 35 10.1016/j.krcp.2012.06.007 false true Reference 50002349 /api/reference/50002349 36. Dankó T, Petővári G, Sztankovics D, Moldvai D, Raffay R, Lőrincz P, et al. Rapamycin Plus Doxycycline Combination Affects Growth Arrest and Selective Autophagy-Dependent Cell Death in Breast Cancer Cells. Int J Mol Sci. 2021;22:8019., DOI: 10.3390/ijms22158019 36 10.3390/ijms22158019 false true Reference 50002350 /api/reference/50002350 37. Krencz I, Vetlényi E, Dankó T, Petővári G, Moldvai D, Sztankovics D, et al. Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics. Int J Mol Sci. 2022;23:10587., DOI: 10.3390/ijms231810587 37 10.3390/ijms231810587 false true Reference 50002351 /api/reference/50002351 38. Sztankovics D, Moldvai D, Petővári G, Gelencsér R, Krencz I, Raffay R, et al. 3D bioprinting and the revolution in experimental cancer model systems-A review of developing new models and experiences with in vitro 3D bioprinted breast cancer tissue-mimetic structures. Pathol Oncol Res. 2023;29:1610996., DOI: 10.3389/pore.2023.1610996 38 10.3389/pore.2023.1610996 false true Reference 50002352 /api/reference/50002352 39. Panizo S, Martínez-Arias L, Alonso-Montes C, Cannata P, Martín-Carro B, Fernández-Martín JL, et al. Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences. Int J Mol Sci. 2021;22:408., DOI: 10.3390/ijms22010408 39 10.3390/ijms22010408 false true Reference 50002353 /api/reference/50002353 40. Anders HJ, Vielhauer V, Schlöndorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int. 2003;63:401–15., DOI: 10.1046/j.1523-1755.2003.00750.x 40 10.1046/j.1523-1755.2003.00750.x false true Reference 50002354 /api/reference/50002354 41. To WS, Midwood KS. Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenes Tissue Repair. 2011;4:21., DOI: 10.1186/1755-1536-4-21 41 10.1186/1755-1536-4-21 false true Reference 50002355 /api/reference/50002355 42. Higgins SP, Tang Y, Higgins CE, Mian B, Zhang W, Czekay RP, et al. TGF-β1/p53 signaling in renal fibrogenesis. Cell Signal. 2018;43:1–10., DOI: 10.1016/j.cellsig.2017.11.005 42 10.1016/j.cellsig.2017.11.005 false true Reference 50002356 /api/reference/50002356 43. Cernaro V, Lacquaniti A, Donato V, Fazio MR, Buemi A, Buemi M. Fibrosis, regeneration and cancer: what is the link? Nephrol Dial Transpl. 2012;27:21–7., DOI: 10.1093/ndt/gfr567 43 10.1093/ndt/gfr567 false true Reference 50002357 /api/reference/50002357 44. Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263., DOI: 10.1038/s41392-021-00658-5 44 10.1038/s41392-021-00658-5 false true Reference 50002358 /api/reference/50002358 45. Satake M, Sakuraba H, Hiraga H, Yoshida S, Akemoto Y, Ota S, et al. Tacrolimus Up-regulates Expression of TGFβ Receptor Type II via ERK, Providing Protection Against Intestinal Epithelial Injury. Vivo. 2022;36:1684–93., DOI: 10.21873/invivo.12880 45 10.21873/invivo.12880 false true Reference 50002359 /api/reference/50002359 46. Jahr H, van der Windt AE, Timur UT, Baart EB, Lian WS, Rolauffs B, et al. Physosmotic Induction of Chondrogenic Maturation Is TGF-β Dependent and Enhanced by Calcineurin Inhibitor FK506. Int J Mol Sci. 2022;23:5110., DOI: 10.3390/ijms23095110 46 10.3390/ijms23095110 false true Reference 50002360 /api/reference/50002360 47. Chandra Jena B, Sarkar S, Rout L, Mandal M. The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF-β in CAF mediated tumor progression and therapeutic resistance. Cancer Lett. 2021;520:222–32., DOI: 10.1016/j.canlet.2021.08.002 47 10.1016/j.canlet.2021.08.002 false true Reference 50002361 /api/reference/50002361 48. Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. 2022;21:104., DOI: 10.1186/s12943-022-01569-x 48 10.1186/s12943-022-01569-x false true Reference 50002362 /api/reference/50002362 49. Datta D, Contreras AG, Basu A, Dormond O, Flynn E, Briscoe DM, et al. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res. 2009;69:8902–9., DOI: 10.1158/0008-5472.CAN-09-1404 49 10.1158/0008-5472.CAN-09-1404 false true Reference 50002363 /api/reference/50002363 50. Basu A, Banerjee P, Contreras AG, Flynn E, Pal S. Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. PLoS One. 2011;6:e23919., DOI: 10.1371/journal.pone.0023919 50 10.1371/journal.pone.0023919 false true Reference 50002364 /api/reference/50002364 51. Rodriguez-Rodriguez AE, Donate-Correa J, Rovira J, Cuesto G, Luis-Ravelo D, Fernandes MX, et al. Inhibition of the mTOR pathway: A new mechanism of β cell toxicity induced by tacrolimus. Am J Transpl. 2019;19:3240–9., DOI: 10.1111/ajt.15483 51 10.1111/ajt.15483 false true Reference 50002365 /api/reference/50002365 52. Asleh R, Clavell AL, Pereira NL, Smith B, Briasoulis A, Alnsasra H, et al. Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. J Am Coll Cardiol. 2019;73:2676–88., DOI: 10.1016/j.jacc.2019.03.499 52 10.1016/j.jacc.2019.03.499 false true Reference 50002366 /api/reference/50002366 53. Reynold IL-S, Panpan C, Lakshmi N, Ashar A, Sunil P, David JC. Sirolimus use improves cancer-free survival following transplantation: A single center 12-year analysis. Transplant Rep. 2020;5:100040. 53 false true Reference 50002367 /api/reference/50002367 54. Kampaktsis PN, Doulamis IP, Asleh R, Makri E, Kalamaras I, Papastergiopoulos C, et al. Characteristics, Predictors, and Outcomes of Early mTOR Inhibitor Use After Heart Transplantation: Insights From the UNOS Database. J Am Heart Assoc. 2022;11:e025507., DOI: 10.1161/JAHA.122.025507 54 10.1161/JAHA.122.025507 false true Reference 50002368 /api/reference/50002368 55. Wen SY, Li CH, Zhang YL, Bian YH, Ma L, Ge QL, et al. Rictor is an independent prognostic factor for endometrial carcinoma. Int J Clin Exp Pathol. 2014;7:2068–78. 55 false true Reference 50002369 /api/reference/50002369 56. Cao RZ, Min L, Liu S, Tian RY, Jiang HY, Liu J, et al. Rictor Activates Cav 1 Through the Akt Signaling Pathway to Inhibit the Apoptosis of Gastric Cancer Cells. Front Oncol. 2021;11:641453., DOI: 10.3389/fonc.2021.641453 56 10.3389/fonc.2021.641453 false true Reference 50002370 /api/reference/50002370 57. Sticz T, Molnár A, Márk Á, Hajdu M, Nagy N, Végső G, et al. mTOR activity and its prognostic significance in human colorectal carcinoma depending on C1 and C2 complex-related protein expression. J Clin Pathol. 2017;70:410–6., DOI: 10.1136/jclinpath-2016-203913 57 10.1136/jclinpath-2016-203913 false true Reference 50002371 /api/reference/50002371 58. Krencz I, Sebestyen A, Papay J, Lou Y, Lutz GF, Majewicz TL, et al. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma. Hum Pathol. 2019;93:74–80., DOI: 10.1016/j.humpath.2019.08.018 58 10.1016/j.humpath.2019.08.018 false true Reference 50002372 /api/reference/50002372 59. D’Arcy ME, Coghill AE, Lynch CF, Koch LA, Li J, Pawlish KS, et al. Survival after a cancer diagnosis among solid organ transplant recipients in the United States. Cancer. 2019;125:933–42., DOI: 10.1002/cncr.31782 59 10.1002/cncr.31782 false true Reference 50002373 /api/reference/50002373 60. Shigematsu T, Tajima S, Fu R, Zhang M, Itoyama Y, Tsuchimoto A, et al. The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats. Life Sci. 2022;288:120150., DOI: 10.1016/j.lfs.2021.120150 60 10.1016/j.lfs.2021.120150 false true /api/publication/34573098 Moldvai Dorottya et al. Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas. (2024) BRITISH JOURNAL OF CANCER 0007-0920 1532-1827 130 7 1119-1130<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10078438"><a href="/gui2/?type=authors&mode=browse&sel=10078438" target="_blank">Moldvai Dorottya (<span class="authorship-author-name">Moldvai Dorottya</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10074525"><a href="/gui2/?type=authors&mode=browse&sel=10074525" target="_blank">Sztankovics Dániel (<span class="authorship-author-name">Sztankovics Dániel</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10065723"><a href="/gui2/?type=authors&mode=browse&sel=10065723" target="_blank">Dankó Titanilla (<span class="authorship-author-name">Dankó Titanilla</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10059474"><a href="/gui2/?type=authors&mode=browse&sel=10059474" target="_blank">Vetlényi Enikő (<span class="authorship-author-name">Vetlényi Enikő Judit</span> <span class="authorAux-mtmt"> Onkológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10051987"><a href="/gui2/?type=authors&mode=browse&sel=10051987" target="_blank">Petővári Gábor (<span class="authorship-author-name">Petővári Gábor</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10035394"><a href="/gui2/?type=authors&mode=browse&sel=10035394" target="_blank">Márk Ágnes (<span class="authorship-author-name">Márk Ágnes</span> <span class="authorAux-mtmt"> Hematopatológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10024162"><a href="/gui2/?type=authors&mode=browse&sel=10024162" target="_blank">Patonai Attila (<span class="authorship-author-name">Patonai Attila</span> <span class="authorAux-mtmt"> belgyógyászat, patológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Sebészeti, Transzplantációs és Gasztroenterológiai Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10024127"><a href="/gui2/?type=authors&mode=browse&sel=10024127" target="_blank">Végső Gyula (<span class="authorship-author-name">Végső Gyula</span> <span class="authorAux-mtmt"> sebészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Sebészeti, Transzplantációs és Gasztroenterológiai Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10024125"><a href="/gui2/?type=authors&mode=browse&sel=10024125" target="_blank">Piros László (<span class="authorship-author-name">Piros László</span> <span class="authorAux-mtmt"> sebészet</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Sebészeti, Transzplantációs és Gasztroenterológiai Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10032730"><a href="/gui2/?type=authors&mode=browse&sel=10032730" target="_blank">Hosszú Ádám (<span class="authorship-author-name">Hosszú Ádám</span> <span class="authorAux-mtmt"> nephrológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/<span title="Gyermekgyógyászati Klinika">GYGYK</span>/MTA-SE Lendület Diabétesz Kutatócsoport; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Gyermekgyógyászati Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10023572"><a href="/gui2/?type=authors&mode=browse&sel=10023572" target="_blank">Pápay Judit (<span class="authorship-author-name">Pápay Judit</span> <span class="authorAux-mtmt"> Patológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10051986"><a href="/gui2/?type=authors&mode=browse&sel=10051986" target="_blank">Krencz Ildikó^** (<span class="authorship-author-name">Krencz Ildikó</span> <span class="authorAux-mtmt"> Tüdődaganatok</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000745"><a href="/gui2/?type=authors&mode=browse&sel=10000745" target="_blank">Sebestyén Anna ✉ (<span class="authorship-author-name">Sebestyén Anna</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Patológiai és Kísérleti Rákkutató Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;34573098" target="_blank">Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas</a></div> <div> <span class="journal-title">BRITISH JOURNAL OF CANCER</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0007-0920">0007-0920</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1532-1827">1532-1827</a>)</span>: <span class="journal-volume">130</span> <span class="journal-issue">7</span> <span class="page"> pp 1119-1130 </span> <span class="year">(2024)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1038/s41416-024-02597-8" target="_blank" href="https://doi.org/10.1038/s41416-024-02597-8"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001161221700001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001161221700001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85184499042" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85184499042"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="38341510" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38341510&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Oncology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cancer Research&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 4</span> | Független: 3 | Függő: 1 | Nem jelölt: 0 | WoS jelölt: 4 | Scopus jelölt:&nbsp;4 | WoS/Scopus jelölt:&nbsp;4 | DOI jelölt:&nbsp;4 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;34573098&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 8 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 34573098</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (National Bionics Programme ED_17-1-2017-0009) Támogató: NKFIH, (TKP2021-EGA-24), (FK-128404) Támogató: NKFIH, (K-142799) Támogató: NKFI, A szervtranszplantáció során jelentkező oxigénhiányos károsodás molekuláris mechanizmusai és új k...(PD-131637) Támogató: OTKA, Az orvos-, egészségtudományi- és gyógyszerészképzés tudományos műhelyeinek fejlesztése(EFOP-3.6.3-VEKOP-16-2017-00009) Támogató: EFOP-VEKOP, (ÚNKP-22-4-I-SE-12), (LP2021-3/2021), (Open access funding provided by Semmelweis University) </div> <div class="lastModified">Utolsó módosítás: 2026.09.15. 13:44 Gere Tamásné (SE_KK_Admin5_GT, admin) </div> </div></div>